Etoricoxib

Chemical formula: C₁₈H₁₅ClN₂O₂S  Molecular mass: 358.842 g/mol  PubChem compound: 123619

Therapeutic indications

Etoricoxib is indicated for:

Ankylosing spondylitis

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Etoricoxib is indicated in adults and adolescents 16 years of age and older for the symptomatic relief of ankylosing spondylitis.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Osteoarthritis

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Etoricoxib is indicated in adults and adolescents 16 years of age and older for the symptomatic relief of osteoarthritis (OA).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Acute gouty arthritis

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Etoricoxib is indicated in adults and adolescents 16 years of age and older for the symptomatic relief of pain and signs of inflammation associated with acute gouty arthritis.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Rheumatoid arthritis

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Etoricoxib is indicated in adults and adolescents 16 years of age and older for the symptomatic relief of rheumatoid arthritis (RA).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Postoperative dental surgery pain

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Etoricoxib is indicated in adults and adolescents 16 years of age and older for the short-term treatment of moderate pain associated with dental surgery.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Etoricoxib is contraindicated in the following cases:

Pregnancy

Pregnancy

Lactation

Lactation

Severe hepatic dysfunction

Hepatic failure stage IV

Inflammatory bowel disease

Inflammatory bowel disease

Congestive heart failure (NYHA II-IV)

at least one of
Congestive heart failure
Heart failure New York Heart Assosiation Class IΙΙ
Heart failure New York Heart Assosiation Class IV

Hypertension

Hypertension

Ischemic heart disease

Ischemic heart disease

Peripheral arterial occlusive disease

Peripheral arterial occlusive disease

Cerebrovascular disease

Cerebrovascular disease

Severe renal impairment

at least one of

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2022: ARCOXIA Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈